Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Heron Therapeutics Inc (HRTX) vs Lockheed Martin Corporation (LMT) Price & Performance

Heron Therapeutics IncTrade
Lockheed Martin CorporationTrade

Price performance (Past 24H)

Key statistics

Heron Therapeutics Inc vs Lockheed Martin Corporation — how do they compare? Heron Therapeutics Inc trades at $0.32 (market cap $63.41M), while Lockheed Martin Corporation trades at $597.01 (market cap $139.20B). The key difference: Lockheed Martin Corporation is far larger — about 2195.2× Heron Therapeutics Inc's market cap, and Lockheed Martin Corporation pays a 2.29% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.

HRTXLMT
Market Cap
$63.41M$139.20B
Sector
HealthIndustrials
52-Week High
$1.49$676.70
52-Week Low
$0.32$431.56
Enterprise Value
$161.31M$155.95B
Dividend Yield
2.29%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Heron Therapeutics Inc

Heron Therapeutics (HRTX) trades at $0.49, down 1.64% today, with a bearish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7M but missed earnings expectations with a $0.03 loss per share. Despite negative net income margins, HRTX maintains strong analyst support with 94.7% buy ratings. Recent news highlights patent litigation developments and quarterly earnings underperformance.

HRTX faces significant fundamental challenges with persistent losses and declining revenue projections, though analyst consensus remains overwhelmingly bullish. Investment opportunity exists if the company can achieve profitability and meet growth targets, but risks include ongoing operational losses, competitive pressures, and execution challenges in the biotechnology sector.

Lockheed Martin Corporation

Lockheed Martin (LMT) trades at $587.95, up 0.9% with bullish technical signals and strong institutional support. The company reported mixed Q2 2026 earnings with a beat on EPS ($7.94 vs. $7.22 expected) but maintains a record $230B backlog. Valuation metrics show a P/E of 21.68 and ROE of 89.16%, though recent quarters saw earnings misses. Technical indicators suggest bullish momentum with key resistance at $592.

Outlook remains positive driven by defense contract wins and production expansion, but risks include execution on massive backlog and debt levels. Analyst consensus is bullish with $608 price target representing 3.4% upside. The stock offers stability through dividends ($3.45 quarterly) amid geopolitical demand for defense systems.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Heron Therapeutics Inc

Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.

Read more on HRTX

About Lockheed Martin Corporation

Lockheed Martin is the largest defense contractor globally and has dominated the Western market for high-end fighter aircraft since the F-35 program was awarded in 2001. Lockheed's largest segment is aeronautics, which is dominated by the massive F-35 program. Lockheed's remaining segments are rotary and mission systems, which is mainly the Sikorsky helicopter business.

Read more on LMT